| scholarly article | Q13442814 |
| P50 | author | Catherine Cowie | Q64157246 |
| William H. Herman | Q64427353 | ||
| Maureen I. Harris | Q64482010 | ||
| Richard C. Eastman | Q126949166 | ||
| P2093 | author name string | Maier W | |
| Dong F | |||
| Garfield SA | |||
| Javitt JC | |||
| Dasbach EJ | |||
| Zbrozek AS | |||
| Copley-Merriman C | |||
| Eastman JF | |||
| Kotsanos J | |||
| Manninen D | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 725-734 | |
| P577 | publication date | 1997-05-01 | |
| P1433 | published in | Diabetes Care | Q5270111 |
| P1476 | title | Model of complications of NIDDM. I. Model construction and assumptions. | |
| P478 | volume | 20 |
| Q38705217 | A Systematic Review of Cost-Effectiveness Models in Type 1 Diabetes Mellitus |
| Q74581790 | A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus |
| Q31047512 | A critical review of mathematical models and data used in diabetology |
| Q36519198 | A model of long-term metabolic progression of type 2 diabetes mellitus for evaluating treatment strategies |
| Q40471646 | A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). |
| Q48698887 | A taxonomy of model structures for economic evaluation of health technologies |
| Q37264494 | A1c variability can predict coronary artery disease in patients with type 2 diabetes with mean a1c levels greater than 7. |
| Q35612603 | Adherence to guidelines and its effects on hospitalizations with complications of type 2 diabetes. |
| Q33519176 | Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT) |
| Q40782006 | Alcohol consumption among patients with diabetes: a survey-based cross-sectional study of Danish adults with diabetes |
| Q40788011 | Are predictors of coronary heart disease and lower-extremity arterial disease in type 1 diabetes the same? A prospective study |
| Q50791363 | Assessing the natural course of diabetic retinopathy: a population-based study in Kinmen, Taiwan. |
| Q74348457 | Clinical impact and health economic consequences of posttransplant type 2 diabetes mellitus |
| Q61635297 | Continuous Monitoring of Glucose for Type 1 Diabetes: A Health Technology Assessment |
| Q92710777 | Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada |
| Q77223583 | Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group |
| Q50749591 | Cost effectiveness of ACE inhibitor treatment for patients with type 1 diabetes mellitus. |
| Q37333383 | Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. |
| Q35734015 | Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective |
| Q24793101 | Cost of managing complications resulting from type 2 diabetes mellitus in Canada |
| Q50145776 | Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States |
| Q36235072 | Cost-effectiveness of a national population-based screening program for type 2 diabetes: the Brazil experience |
| Q33873025 | Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes |
| Q58476517 | Cost-effectiveness of glycemic control and ophthalmological care in diabetic retinopathy |
| Q48097169 | Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes. |
| Q36519203 | Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. |
| Q34726534 | Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in sweden |
| Q38924071 | Description of a New Predictive Modeling Approach That Correlates the Risk and Associated Cost of Well-Defined Diabetes-Related Complications With Changes in Glycated Hemoglobin (HbA1c). |
| Q46900712 | Determining the Value of Disease Management Programs |
| Q28689671 | Development of an economic evaluation of diagnostic strategies: the case of monogenic diabetes |
| Q79207704 | Diabetes Modeling |
| Q53338014 | Diabetes nephropathy in the Netherlands: a cost effectiveness analysis of national clinical guidelines. |
| Q54489626 | Differential MMP-9 activity in CD34⁺progenitor cell-derived foam cells from diabetic and normoglycemic patients. |
| Q49313229 | Do routine eye exams improve vision? |
| Q83016278 | Does comorbidity affect the benefit of intensive glycemic control in older patients with type 2 diabetes mellitus? |
| Q90392805 | Economic Modelling of Chronic Kidney Disease: A Systematic Literature Review to Inform Conceptual Model Design |
| Q30278856 | Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 Diabetes in Canada |
| Q56380088 | Economic Value of Improved Accuracy for Self-Monitoring of Blood Glucose Devices for Type 1 and Type 2 Diabetes in England |
| Q47594626 | Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes |
| Q44010115 | Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada |
| Q28083249 | Economics of Team-based Care in Controlling Blood Pressure: A Community Guide Systematic Review |
| Q34988073 | Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. |
| Q55004248 | Effectiveness of text message based, diabetes self management support programme (SMS4BG): two arm, parallel randomised controlled trial. |
| Q47116602 | External validation of type 2 diabetes computer simulation models: definitions, approaches, implications and room for improvement-a protocol for a systematic review. |
| Q44236255 | Health and economic effects of adding nateglinide to metformin to achieve dual control of glycosylated hemoglobin and postprandial glucose levels in a model of type 2 diabetes mellitus |
| Q24797434 | Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K |
| Q37639785 | How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review |
| Q89220463 | Impact of Reducing Glycated Hemoglobin on Healthcare Costs Among a Population with Uncontrolled Diabetes |
| Q37319259 | Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences |
| Q33600126 | Incidence and long-term cost of steroid-related side effects after renal transplantation |
| Q34982099 | Insulin lispro: a pharmacoeconomic review of its use in diabetes mellitus |
| Q50020892 | Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes |
| Q57153294 | Life Expectancy Predictions for Older Diabetic Patients as Estimated by Physicians and a Prognostic Model |
| Q36519211 | Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain. |
| Q90017415 | Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India |
| Q41603287 | Long-term health care outcomes in diabetes. Economic and political implications |
| Q40524060 | Management of French patients with type 2 diabetes mellitus in medical general practice: report of the Mediab observatory |
| Q36354226 | Model-based evaluation of diabetic foot prevention strategies in Austria. |
| Q44171229 | Optimal allocation of resources across four interventions for type 2 diabetes |
| Q50653724 | Patient-level estimates of the cost of complications in diabetes in a managed-care population. |
| Q35207593 | Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes |
| Q34536093 | Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making |
| Q44139569 | Pharmacokinetics of rosiglitazone in patients with end-stage renal disease |
| Q40902717 | Policy evaluation in diabetes prevention and treatment using a population-based macro simulation model: the MICADO model |
| Q74409946 | Preventing diabetes complications: living up to the promise |
| Q33752755 | Prevention and treatment of microvascular and neuropathic complications of diabetes |
| Q77098018 | Prevention of type 2 diabetes |
| Q37437118 | Projecting the future diabetes population size and related costs for the U.S. |
| Q36107313 | Quality improvement implementation and disparities: the case of the health disparities collaboratives |
| Q46517834 | Requisite models for strategic commissioning: the example of type 1 diabetes. |
| Q51553902 | Screening for Type 2 diabetes mellitus: a decision analytic approach. |
| Q33792943 | Screening for diabetes: what are we really doing? |
| Q48630728 | Staged diabetes management: computerizing a disease state management program |
| Q37193604 | Stratified patient-centered care in type 2 diabetes: a cluster-randomized, controlled clinical trial of effectiveness and cost-effectiveness |
| Q38983622 | Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus. |
| Q37309996 | Tailored Case Management for Diabetes and Hypertension (TEACH-DM) in a community population: study design and baseline sample characteristics |
| Q35129365 | The Economics of Screening and Treatment in Type 2 Diabetes Mellitus |
| Q73195349 | The Mt. Hood challenge: cross-testing two diabetes simulation models |
| Q33873097 | The cost-effectiveness of continuous glucose monitoring in type 1 diabetes |
| Q36295307 | The cost-effectiveness of improving diabetes care in U.S. federally qualified community health centers |
| Q41603364 | The cost-effectiveness of intensive therapy for diabetes mellitus |
| Q44624863 | The cost-effectiveness of the Dose Adjustment for Normal Eating (DAFNE) structured education programme: an update using the Sheffield Type 1 Diabetes Policy Model |
| Q36925939 | The effect of comorbid illness and functional status on the expected benefits of intensive glucose control in older patients with type 2 diabetes: a decision analysis |
| Q50701847 | The evaluation of screening policies for diabetic retinopathy using simulation. |
| Q48181829 | The experiences of people with diabetes-related lower limb amputation at the Komfo Anokye Teaching Hospital (KATH) in Ghana |
| Q73195343 | The global diabetes model: user friendly version 3.0. |
| Q41556880 | The impact of cardiovascular disease on people with diabetes: the potential for prevention. |
| Q36537695 | The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes |
| Q34660664 | The role of models within economic analysis: focus on type 2 diabetes mellitus. |
| Q30625765 | Towards renewed health economic simulation of type 2 diabetes: risk equations for first and second cardiovascular events from Swedish register data |
| Q48230405 | Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). |
| Q34332236 | Validation of the IHE Cohort Model of Type 2 Diabetes and the impact of choice of macrovascular risk equations |
| Q42414170 | Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model |
| Q41719464 | Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study |
Search more.